Puma Biotechnology Inc (PBYI.N)

PBYI.N on New York Stock Exchange

190.82USD
26 Dec 2014
Price Change (% chg)

$0.86 (+0.45%)
Prev Close
$189.96
Open
$190.47
Day's High
$193.00
Day's Low
$190.00
Volume
24,528
Avg. Vol
46,204
52-wk High
$278.50
52-wk Low
$53.80

PBYI.N

Chart for PBYI.N

About

Puma Biotechnology, Inc. is a development-stage biopharmaceutical company that acquires and develops products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to... (more)

Overall

Beta: --
Market Cap (Mil.): $5,752.85
Shares Outstanding (Mil.): 30.15
Dividend: --
Yield (%): --

Financials

  PBYI.N Industry Sector
P/E (TTM): -- 159.35 38.84
EPS (TTM): -3.70 -- --
ROI: -92.57 -0.82 18.26
ROE: -93.44 -1.98 19.12
Search Stocks

UPDATE 1-Puma names Rihanna as women's creative director

* Puma spending on marketing to catch up with Nike, Adidas

16 Dec 2014

Puma Biotech says cancer drug fails mid-stage study

- Puma Biotechnology Inc said its cancer drug failed as a primary treatment for breast cancer patients in a mid-stage study, sending its shares down 14 percent in extended trading.

13 Nov 2014

UPDATE 1-Puma Biotech says cancer drug fails mid-stage study

Nov 13 - Puma Biotechnology Inc said its cancer drug failed as a primary treatment for breast cancer patients in a mid-stage study, sending its shares down 14 percent in extended trading.

13 Nov 2014

Puma Biotech says cancer drug fails mid-stage study

Nov 13 - Puma Biotechnology Inc said its experimental breast cancer drug failed in a mid-stage study, sending its shares down 14 percent in extended trading.

13 Nov 2014

Healthcare sector sees silver lining in U.S. tax inversion rules

NEW YORK - Investors and bankers have been lamenting the potential death of large cross-border healthcare mergers since the U.S. Treasury Department announced in late September that it would curtail the tax breaks from international deals designed to give U.S. companies a legal home in a low-tax country.

06 Nov 2014

DEALTALK-Healthcare sector sees silver lining in U.S. tax inversion rules

NEW YORK, Nov 6 - Investors and bankers have been lamenting the potential death of large cross-border healthcare mergers since the U.S. Treasury Department announced in late September that it would curtail the tax breaks from international deals designed to give U.S. companies a legal home in a low-tax country.

06 Nov 2014

Puma Biotechnology cancer drug shows positive mid-stage results

- Puma Biotechnology Inc said its experimental lung cancer drug was safe to be administered with an already approved treatment for the disease in a mid-stage study.

29 Sep 2014

Puma Biotechnology cancer drug shows positive mid-stage results

Sept 29 - Puma Biotechnology Inc said its experimental lung cancer drug was safe to be administered with an already approved treatment for the disease in a mid-stage study.

29 Sep 2014

L'Oreal, Puma sign licence agreement for beauty products

PARIS, Sept 26 - French cosmetics giant L'Oreal said on Friday it had signed a licence agreement for beauty products with Germany's Puma that will become effective on Jan. 1.

26 Sep 2014

Puma renews sponsorship deal with Czech soccer FA

BERLIN, Sept 8 - German sportswear company Puma said it has renewed its partnership with the Czech Republic Football Association, extending a sponsorship deal that has been running since 1995.

08 Sep 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks